treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to mepolizumab or excipients. ...
Detailed Mepolizumab dosage information What happens if I miss a dose?If you miss a dose, inject a dose as soon as possible. Then continue (resume) your injection on your regular dosing schedule.If you do not notice that you have missed a dose until it is time for your next scheduled ...
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Hypersensitivity Reactions Inform patients that hypersensitivity reactions (e.g., angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. Instruct...
treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause. IMPORTANT SAFETY INFORMATION References Weller PF, Spencer LA. Functions of tissue-resident eosinophils.Nat Rev Immunol.2017;17...
¶Severe asthma patients rated the Autoinjector as easy-to-use after training. See fullInstructions for Use. At home not for you? No problem. You can get your NUCALA injections at your specialist’s office every 4 weeks. Just know, it’s important to monitor for serious allergic reactions...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE NUCALA ® is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. [See Clinical Studies (14).] Limitations of Use • NUCALA is not indicated for ...
treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to mepolizumab or excipients. WARNINGS AND PRECAUTIONS Hypersensi...
NUCALA is indicated for the: treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to mepolizumab or excipients....
Review NUCALA patient profiles and dosing information TYPES OF PATIENTS WHO MAY BENEFIT FROM NUCALA These profiles may remind you of patients in your practice. REVIEW PATIENT PROFILES MULTIPLE ADMINISTRATION OPTIONS FOR ONCE-MONTHLY†NUCALA DOSING ...
Mepolizumab, a humanized monoclonal antibody against interleukin-5, significantly reduced asthma exacerbations and improved quality of life among patients